Antiparkinson's Disease Drugs

Correct Answer

C — Peripheral aromatic amino acid decarboxylase inhibitor

Rationale

Carbidopa is classified as a peripheral aromatic amino acid decarboxylase inhibitor. It inhibits the enzyme aromatic amino acid decarboxylase — the enzyme responsible for converting levodopa to dopamine — but only in peripheral tissues, because carbidopa does not cross the blood-brain barrier. Carbidopa is not a dopamine agonist, which would mean directly stimulating dopamine receptors. It is not a dopamine precursor such as levodopa, which is converted to dopamine inside the brain. It is not a monoamine oxidase B inhibitor, which slows the breakdown of dopamine rather than blocking its synthesis from levodopa.

Correct Answer

A — Fixed-dose combination product

Rationale

Carbidopa-levodopa is classified as a fixed-dose combination product — a single formulation containing two drugs in a set ratio. Levodopa is the active antiparkinson agent, a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine inside the brain. Carbidopa is the peripheral decarboxylase inhibitor that protects levodopa from conversion outside the brain. Because levodopa is never given alone in current clinical practice, the fixed combination is the standard formulation. It is not a dopamine agonist, which would directly stimulate dopamine receptors without requiring precursor conversion. It is not a monoamine oxidase B inhibitor or an anticholinergic agent.

Correct Answer

B — Nonselective monoamine oxidase inhibitors

Rationale

Phenelzine and tranylcypromine are both classified as nonselective monoamine oxidase inhibitors — drugs that inhibit both monoamine oxidase A and monoamine oxidase B. This is the class that is contraindicated with levodopa therapy. Selective monoamine oxidase B inhibitors such as selegiline and rasagiline inhibit only the B isoform and are used therapeutically in Parkinson's disease — they are not contraindicated with levodopa. Catechol-O-methyltransferase inhibitors such as entacapone block a different enzyme involved in levodopa metabolism. Dopamine agonists such as pramipexole directly stimulate dopamine receptors.

Correct Answer

D — Selective monoamine oxidase B inhibitor

Rationale

Rasagiline is classified as a selective monoamine oxidase B inhibitor — it selectively inhibits the B isoform of monoamine oxidase, which is the isoform primarily responsible for dopamine metabolism in the brain. This selectivity distinguishes rasagiline from nonselective monoamine oxidase inhibitors such as phenelzine, which inhibit both monoamine oxidase A and monoamine oxidase B and are contraindicated with levodopa. A dopamine precursor such as levodopa is converted to dopamine inside the brain. A peripheral decarboxylase inhibitor such as carbidopa prevents levodopa conversion in peripheral tissues.

Correct Answer

D — Entacapone and tolcapone

Rationale

Entacapone and tolcapone are both classified as catechol-O-methyltransferase inhibitors — drugs that block the enzyme catechol-O-methyltransferase, which is responsible for methylating levodopa in peripheral tissues and converting it to an inactive metabolite. By inhibiting this enzyme, they extend the plasma half-life of levodopa and increase the fraction of each dose that reaches the brain. Selegiline and rasagiline are selective monoamine oxidase B inhibitors, a distinct enzyme inhibitor class that slows dopamine breakdown after it has been formed. Carbidopa and levodopa belong to different classes — carbidopa is a peripheral decarboxylase inhibitor and levodopa is a dopamine precursor. Phenelzine and tranylcypromine are nonselective monoamine oxidase inhibitors, which are contraindicated with levodopa.

Correct Answer

C — Selegiline and rasagiline

Rationale

Selegiline and rasagiline are both classified as selective monoamine oxidase B inhibitors — drugs that selectively inhibit the B isoform of monoamine oxidase, which is responsible for dopamine breakdown in the brain. Both are used therapeutically in Parkinson's disease to prolong dopamine availability. Phenelzine and tranylcypromine are nonselective monoamine oxidase inhibitors that block both monoamine oxidase A and monoamine oxidase B and are contraindicated with levodopa. Entacapone and tolcapone are catechol-O-methyltransferase inhibitors, a distinct enzyme inhibitor class that slows peripheral levodopa metabolism by a different pathway. Carbidopa and levodopa belong to different drug classes — carbidopa is a peripheral decarboxylase inhibitor and levodopa is a dopamine precursor.

Correct Answer

B — Carbidopa does not cross the blood-brain barrier and therefore cannot reach the central nervous system enzyme

Rationale

Carbidopa is excluded from the brain by the blood-brain barrier. Because it cannot enter the central nervous system, it has no access to the aromatic amino acid decarboxylase enzyme present in dopaminergic neurons and other brain cells. The result is that levodopa passes through the peripheral tissues without being converted — thanks to carbidopa's inhibition there — reaches the brain via the large neutral amino acid transporter, and is then freely converted to dopamine by the central enzyme that carbidopa never reaches. This is precisely the pharmacological design of the combination: peripheral protection with central sparing. Carbidopa is not rapidly metabolized before reaching the brain — its exclusion is a structural barrier property, not a metabolic one. There is no separate isoform of the enzyme in the brain, and efflux pumps are not the mechanism of carbidopa's peripheral confinement.

Correct Answer

D — Approximately 75 percent

Rationale

When levodopa is given without carbidopa, the vast majority of each oral dose is converted to dopamine in peripheral tissues — primarily the gut wall and liver — before it can reach the brain. Adding carbidopa blocks this peripheral conversion, allowing a much greater fraction of each dose to pass through the periphery intact and enter the brain via the large neutral amino acid transporter. The result is that the required levodopa dose is typically reduced by approximately 75 percent. This reduction has two practical benefits: it lowers the total dopamine burden in the periphery, reducing adverse effects such as nausea and orthostatic hypotension, and it makes treatment more economical and better tolerated at therapeutic doses.

Correct Answer

A — Carbidopa prevents peripheral dopamine formation, reducing stimulation of the chemoreceptor trigger zone

Rationale

Orthostatic hypotension is an early adverse effect of levodopa-carbidopa caused by peripheral dopamine. Even with carbidopa substantially reducing peripheral conversion of levodopa, some peripheral dopamine is still produced. Dopamine acting on peripheral vascular dopamine receptors causes vasodilation — a reduction in vascular resistance that lowers blood pressure. When the patient stands, the normal compensatory vasoconstriction that prevents blood pressure from falling is impaired by dopamine-mediated vasodilation, producing the orthostatic drop in pressure and the associated dizziness. This is a peripheral effect of dopamine, not a central one — central dopamine does not directly regulate standing blood pressure through this mechanism. Carbidopa does not block norepinephrine release, and levodopa does not interfere with norepinephrine synthesis at sympathetic nerve terminals in this clinical context.

Correct Answer

C — Levodopa has a short plasma half-life of approximately one to two hours, producing intermittent dopamine delivery that the brain cannot buffer as neurons are lost

Rationale

Levodopa has a short plasma half-life of approximately one to two hours. In early Parkinson's disease, the brain can compensate for this intermittent delivery because surviving dopaminergic neurons retain some capacity to store dopamine and release it steadily between doses. As the disease progresses and more neurons are lost, this buffering capacity disappears. Motor control then becomes directly tied to the rise and fall of plasma levodopa levels — producing the predictable end-of-dose deterioration called wearing-off. This is a pharmacokinetic limitation of levodopa itself, not a change in receptor sensitivity or drug efficacy at the molecular level. Levodopa is not highly protein-bound, so protein binding does not limit its therapeutic activity. First-pass metabolism of levodopa occurs in the gut wall and liver and contributes to the high doses required when carbidopa is absent, but this is a bioavailability concern rather than the explanation for end-of-dose motor fluctuations. Transporter saturation at the large neutral amino acid transporter is a real clinical concern — dietary amino acids compete with levodopa for brain entry — but the wearing-off pattern is explained by levodopa's short half-life and the progressive loss of neuronal buffering capacity.

Correct Answer

B — Starting with a dopamine agonist delays the onset of levodopa-associated motor complications such as wearing-off and dyskinesias

Rationale

Younger patients with Parkinson's disease face a longer disease course and will require antiparkinson therapy for many more years than older patients. Levodopa is the most effective agent available, but long-term use is associated with motor complications — wearing-off and dyskinesias — that develop in the majority of patients after five or more years of therapy. These complications are driven by the pulsatile dopaminergic stimulation that results from levodopa's short half-life. By initiating therapy with a dopamine agonist — which has a longer half-life and provides more continuous receptor stimulation — the total cumulative exposure to pulsatile levodopa stimulation is reduced, delaying the onset of motor complications. Levodopa remains more effective for symptom control and is added when the agonist alone provides insufficient benefit. Dopamine agonists have not been proven to provide neuroprotection, and the strategy is not based on differential nausea sensitivity.

Correct Answer

D — Inhibition of both monoamine oxidase A and monoamine oxidase B prevents peripheral dopamine breakdown, causing accumulation and hypertensive crisis

Rationale

Monoamine oxidase A and monoamine oxidase B are both involved in the peripheral metabolism of catecholamines including dopamine. When a patient on levodopa-carbidopa takes a nonselective monoamine oxidase inhibitor — which blocks both isoforms — the dopamine produced from levodopa in peripheral tissues cannot be broken down. Dopamine accumulates in the bloodstream, causes profound vasoconstriction and adrenergic stimulation, and can precipitate a hypertensive crisis with potentially fatal consequences. Selective monoamine oxidase B inhibitors such as selegiline and rasagiline preserve enough monoamine oxidase A activity to handle peripheral dopamine at therapeutic doses and are used therapeutically rather than being contraindicated. The other options describe mechanisms that are pharmacologically inaccurate — nonselective monoamine oxidase inhibitors do not affect the large neutral amino acid transporter, do not induce decarboxylase, and do not displace levodopa from protein binding.

Correct Answer

A — Dopamine excess in the mesolimbic and mesocortical pathways

Rationale

Levodopa is converted to dopamine throughout the brain, not only in the nigrostriatal pathway where it is therapeutically needed. The mesolimbic pathway — projecting from the ventral tegmental area to limbic structures — and the mesocortical pathway — projecting to the prefrontal cortex — are both exposed to this dopamine. Excessive stimulation of these pathways is responsible for the psychotic symptoms and hallucinations that can develop with levodopa therapy, particularly in older patients and those with preexisting cognitive impairment. This is precisely why managing Parkinson's disease psychosis is challenging: the dopaminergic therapy needed for motor control simultaneously overstimulates the pathways that mediate psychosis. Peripheral dopamine cannot cross the blood-brain barrier, so peripheral dopamine excess is not the cause of these central effects.

Correct Answer

C — It produces no antiparkinsonian effect because it has no mechanism to increase dopamine in the brain

Rationale

Carbidopa acts solely by inhibiting aromatic amino acid decarboxylase in peripheral tissues, protecting levodopa from premature conversion outside the brain. When given without levodopa, there is no dopamine precursor to protect — carbidopa has nothing to act on that would increase brain dopamine. It does not stimulate dopamine receptors, does not inhibit dopamine breakdown, and does not block cholinergic receptors. Its pharmacological role is entirely dependent on the presence of levodopa. This is why carbidopa is always formulated and administered as a fixed combination with levodopa. Carbidopa does not cross the blood-brain barrier and therefore cannot inhibit decarboxylase in the striatum — the central enzyme remains fully active, which is precisely the design of the combination.

Correct Answer

D — Peripheral dopamine causing vasodilation in systemic blood vessels

Rationale

When levodopa is given without carbidopa, most of each dose is converted to dopamine in peripheral tissues before reaching the brain. This peripheral dopamine circulates in the bloodstream and reaches the chemoreceptor trigger zone — a specialized region of the medulla that lies outside the blood-brain barrier and is therefore exposed to plasma dopamine. Stimulation of dopamine receptors in the chemoreceptor trigger zone triggers nausea and vomiting. Carbidopa prevents peripheral aromatic amino acid decarboxylase from converting levodopa to dopamine, dramatically reducing plasma dopamine concentrations and eliminating the stimulus for chemoreceptor trigger zone activation. Carbidopa does not cross the blood-brain barrier, so it cannot act on any brain structure directly. It does not block dopamine receptors and does not alter the absorption rate of levodopa.

Correct Answer

B — Carbidopa reduces peripheral dopamine production, decreasing the dopamine-mediated vasodilation and cardiac stimulation that caused her symptoms

Rationale

When levodopa is given without carbidopa, the majority of each dose is converted to dopamine in peripheral tissues. This peripheral dopamine causes vasodilation by stimulating dopamine receptors in blood vessel walls, producing orthostatic hypotension, and can stimulate cardiac receptors, causing palpitations and arrhythmias. Carbidopa blocks peripheral aromatic amino acid decarboxylase, substantially reducing the amount of dopamine produced outside the brain. With less peripheral dopamine circulating, the vasodilatory and cardiac stimulatory effects are markedly reduced — accounting for the resolution of this patient's cardiovascular symptoms. Carbidopa does not directly block dopamine receptors in blood vessels, does not compete at adrenergic receptors, and does not alter renal dopamine clearance.

Correct Answer

A — Dopaminergic effects of levodopa can cause mydriasis, which may precipitate acute angle closure in susceptible patients

Rationale

Levodopa has dopaminergic effects in the eye that can cause pupillary dilation — mydriasis. In patients with open-angle glaucoma, this is generally not a concern because the drainage angle remains accessible. However, in patients with narrow-angle glaucoma, the angle between the iris and the cornea is already compromised. Mydriasis can further narrow this angle, obstructing aqueous humor drainage and precipitating an acute angle-closure crisis with a sudden dangerous rise in intraocular pressure. This is why levodopa is not absolutely contraindicated in narrow-angle glaucoma but requires careful monitoring — the risk is real but manageable with ophthalmological supervision. Levodopa does not directly stimulate aqueous humor production, carbidopa does not act on the trabecular meshwork, and central dopamine does not cause retinal vasoconstriction via this mechanism.

Correct Answer

C — Increased dopamine activity from levodopa may exacerbate psychotic symptoms in a patient with a pre-existing psychotic disorder

Rationale

Levodopa increases dopamine activity throughout the brain, including in the mesolimbic and mesocortical pathways that are central to the pathophysiology of psychosis. In patients with schizophrenia, these dopaminergic pathways are already dysregulated, and adding a drug that substantially increases dopamine availability may worsen hallucinations, delusions, or disorganized thinking — even when the antipsychotic medication remains on board. This is why levodopa is not absolutely contraindicated in patients with psychotic disorders but requires careful clinical monitoring. Managing this patient requires balancing motor benefit against psychiatric risk, typically in close coordination between neurology and psychiatry. Levodopa does not compete directly at dopamine receptors with antipsychotic drugs — it increases the substrate dopamine rather than binding to the receptor itself. Carbidopa does not inhibit antipsychotic drug metabolism. Levodopa has no significant serotonin receptor activity.